MedTrace Logo

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

NCT03609398 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2021-02-11

No results posted yet for this study

Summary

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

Conditions

  • Rift Valley Fever

Interventions

BIOLOGICAL

RVF Vaccine

1.0 mL dose given SQ in upper arm

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-04
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609398 on ClinicalTrials.gov